Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 3, 2014, Pages 120-129

  Calarge, Chadi A ^a   Nicol, Ginger ^b   Schlechte, Janet A ^a   Burns, Trudy L ^c  

^a UNIVERSITY OF IOWA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RISPERIDONE; TRIACYLGLYCEROL;

ADOLESCENCE; ADOLESCENT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT; BODY MASS; CARDIOMETABOLIC OUTCOME; CARDIOVASCULAR PARAMETERS; CHILD; CHILDHOOD; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ENERGY BALANCE; FEMALE; FOLLOW UP; HEART RATE; HOMEOSTASIS; HOMEOSTATIC MODEL ASSESSMENT INSULIN RESISTANCE INDEX; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; LINEAR REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL; WAIST CIRCUMFERENCE; WEIGHT GAIN; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; WITHDRAWAL SYNDROME;

ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; RISPERIDONE; SUBSTANCE WITHDRAWAL SYNDROME; WEIGHT GAIN;

EID: 84906329669     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0126     Document Type: Article

References (49)

1. Achenbach TM, Rescorla LA: Manual for the ASEBA School-Age Froms & Profiles. Burlington, VT: Research Center for Children, Youth & Families; 2001.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.
3. Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, Fuchs DC, Ray WA: Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 70:1067-1075, 2013.
4. Bou Khalil R, Richa S: Thyroid adverse effects of psychotropic drugs: A review. Clin Neuropharmacol 34:248-255, 2011.
5. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA: Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psycho-pharmacol 19:101-109, 2009a.
6. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA: Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 19:373-382, 2009b.
7. Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA: Leptin gene-2548G/A variants predict risperidone-Associated weight gain in children and adolescents. Psychiatr Genet 19:320-327, 2009c.
8. Calarge CA, Ivins SD, Motyl KJ, Shibli-Rahhal AA, Bliziotes MM, Schlechte JA: Possible mechanisms for the skeletal effects of an-tipsychotics in children and adolescents. Ther Adv Psycho-pharmacol 3:278-293, 2013.
9. Calarge CA, Nicol G, Xie D, Zimmerman B: Correlates of weight gain during long-term risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health 6:21, 2012a.
10. Calarge CA, Xie D, Fiedorowicz JG, Burns TL, Haynes WG: Rate of weight gain and cardiometabolic abnormalities in children and adolescents. J Pediatr 161:1010-1015 e1011, 2012b.
11. Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA: A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 71:338-347, 2010.
12. Centers for Disease Control:National Health and Nutrition Examination Survey: Anthropometry Procedures Manual. Atlanta: Centers for Disease Control; 2000.
13. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH: Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 157:821-827, 2003.
14. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
15. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T: Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Aff (Millwood) 28:w770-781, 2009.
16. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU: Metabolic and endocrine adverse effects of second-generation an-tipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26:144-158, 2011.
17. De Miguel-Etayo P, Bueno G, Garagorri JM, Moreno LA: Interventions for treating obesity in children. World Rev Nutr Diet 108:98-106, 2013.
18. Dickerman AL, Barnhill JW: Abnormal thyroid function tests in psychiatric patients: A red herring? Am J Psychiatry 169:127-133, 2012.
19. Falkner B, Daniels SR: Summary of the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Hypertension 44:387-388, 2004.
20. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
21. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972.
22. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, Hebebrand J, Theisen FM: Antipsychotic-induced body weight gain: Predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43:620-626, 2009.
23. Gentile S: Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 10:527-542, 2009.
24. Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G, Allison DB: Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Front Psychiatry 3:62, 2012.
25. Greenspan A, Gharabawi G, Kwentus J: Thyroid dysfunction during treatment with atypical antipsychotics. J Clin Psychiatry 66:1334-1335, 2005.
26. Kelly DL, Conley RR: Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or flu-phenazine. J Clin Psychiatry 66:80-84, 2005.
27. Kinon BJ, Gilmore JA, Liu H, Halbreich UM: Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials. Psychoneuroendocrinology 28 Suppl 2:69-82, 2003.
28. Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among U.S. adolescents: A population-based study. Diabetes Care 29:2427-2432, 2006.
29. Lindsay RL, Leone S, Aman MG: Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr (Phila) 43:437-444, 2004.
30. Lipkovich I, Jacobson JG, Hardy TA, Hoffmann VP: Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 8:78, 2008a.
31. Lipkovich I, Kryzhanovskaya LA, Robertson-Plouch C, Xu W, Watson SB, Tohen MF: Predicting Substantial Weight Gain in Olanzapine-Treated Adolescents with Schizophrenia or Bipolar Disorder. Chicago: American Academy of Child and Adolescent Psychiatry; 2008b.
32. Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T: Off-Label Use of Atypical Antipsychotics: An Update. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
33. Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS, Ophoff RA, Meltzer HY, Lencz T, Kennedy JL: Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 69:904-912, 2012.
34. Mankoski R, Stockton G, Manos G, Marler S, McQuade R, Forbes RA, Marcus R: Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. J Child Adolesc Psychopharmacol 23:572-576, 2013.
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985.
36. Mukundan A, Faulkner G, Cohn T, Remington G: Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev:CD006629, 2010. DOI: 10.1002/14651858. C0006629.pub2.
37. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19 Suppl 1:1-93, 2005.
38. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J: Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2:CD005270, 2005.
39. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL: Centers for Disease Control and Prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45-60, 2002.
40. Olfson M, Blanco C, Liu SM, Wang S, Correll CU: National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69:1247-1256, 2012.
41. Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolescent Psychiatry 49:13-23, 2010.
42. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361-1369, 2005.
43. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M: A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163:402-410, 2006.
44. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J: Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 107:22-29, 2009.
45. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term phar-macotherapy for obesity and overweight: Updated meta-Analysis. BMJ 335:1194-1199, 2007.
46. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME: NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): Description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 39:28-38, 2000.
47. Slaughter MH, Lohman TG, Boileau RA, Horswill CA, Stillman RJ, Van Loan MD, Bemben DA: Skinfold equations for estimation of body fatness in children and youth. Hum Biol 60:709-723, 1988.
48. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C: Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsycho-pharmacol 19:629-635, 2009.
49. Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, Sarwar N, Kizer JR, Lawlor DA, Nordestgaard BG, Ridker P, Salomaa V, Stevens J, Woodward M, Sattar N, Collins R, Thompson SG, Whitlock G, Danesh J: Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: Collaborative analysis of 58 prospective studies. Lancet 377:1085-1095, 2011.